Looks like you clickedhttps://www.businesswire.com/news/home/20220816005290/en/FDA-Accepts-Submission-of-Supplemental-New-Drug-Application-for-LYNPARZA%C2%AE-olaparib-in-Combination-With-Abiraterone-and-Prednisone-or-Prednisolone-for-Patients-With-Metastatic-Castration-Resistant-Prostate-Cancer-and-Grants-Priority-Review
If you do not want to visit that page, you can close this browser tab.
